Eli Lilly (LLY) is racing to secure outsourcers to boost production of its obesity drug Zepbound, as the group rolls out its rival to Novo Nordisk’s (NVO) Wegovy, Oliver Barnes and Ian Johnston of The Financial Times reports. Eli Lilly has entered agreements with National Resilience and BSP Pharmaceuticals for the filling and “finishing” of its injector pens, people briefed on the arrangements told the Times. The current demand for GLP-1s, the new class of diabetes and weight-loss drugs, is testing the capacity of manufacturing plants.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- AMD and Eli Lilly: Billionaire Ken Fisher Pours Billions Into These Hot Stocks
- Eli Lilly price target raised to $1,000 from $800 at BofA
- Viking Therapeutics soars after obesity drug trial hits targets
- Leerink sees Viking obesity data as clear win, expects strength in shares
- Deutsche says Viking data shows GLP-1 market may not be duopoly